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Abstract
Background: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and
effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an
excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients
with common cold symptoms.
Methods: In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from
early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days,
compared to placebo.
Results: Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and
the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory
mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1a, IP-10, IL-10, and IFN-a2 were reduced in the Iota-Carrageenan
group.
Conclusions: Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of
early symptoms of common cold. Larger trials are indicated to confirm the results.
Background
Common cold is the most prevalent contagious viral
disease in humans. It is caused by a variety of viral
pathogens with human rhinoviruses (HRV) being the
most abundant ones. Affecting the upper respiratory
system, symptoms like blocked nose, cough and sneez-
ing are most common [1,2]. The socioeconomic losses
associated with viral respiratory tract infections, how-
ever, are huge [3,4] with enormous direct and indirect
costs for our health care system [5]. Colds also pose a
threat for the very young or old, ailing and/or high risk
groups like immunocompromised patients, COPD
patients, asthmatics or lung transplant recipients [1,6].
A wide range of remedies is sold on prescription and
over the counter, but evidence-based medicine systema-
tic reviews conclude that there is still no reliable preven-
tion or cure available and potential serious side effects
of popular products also have to be considered. Given
the multiple causes of common cold, the Cochrane col-
laboration suggested to focus future research efforts on
non virus-specific compounds [7]. Effective formulations
containing antiviral agents are needed for the safe and
efficacious treatment of common cold symptoms and
the containment of viral propagation. Potential side
effects should also be minimal due to the usually nonha-
zardous nature of the indication.
Carrageenan is a sulphated galactose polymer, derived
from Rhodophyceae seaweeds. It is commonly used in
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food preparations and topical products for its gelling
and emulsifying properties. The three main copolymers
are designated as Iota (ι), Kappa () and Lambda (l),
depending on the number and location of sulphate moi-
eties on the hexose scaffold structure [8]. Carrageenan
compounds are on the US Food and Drug Administra-
tion “Generally Recognized as Safe” (GRAS) list of pro-
ducts for consumption and topical applications [9]. In
the pharmaceutical industry, carrageenans are used
in topical formulations at daily dose levels up to 2%
(~30 mg/person).
In a recent publication, we presented our in-vitro find-
ings on the antiviral properties of Iota-Carrageenan
against HRVs (11), which add proof to previous findings
on antiviral properties against other viruses [10-13]. The
presented exploratory study was designed to determine
the magnitude of any effect of Iota-Carrageenan nasal
spray on the severity of common cold symptoms relative
to placebo treatment. The secondary objective was to
analyse effects on biomarker levels and presence of
common cold viruses in nasal lavage samples.
Methods
Subjects
Healthy volunteers > 18 years, who were briefed in
advance and signed the consent declaration prior to any
study-related procedures, were recruited for the study.
Anonymity was guaranteed as study data and informa-
tion on subjects was kept safe to prevent communica-
tion to third parties. Subjects were free to withdraw
from the study at any time without prejudice to further
treatment.
The following symptoms were assessed with inclusion
into the study and on each study day: local symptoms
were sore throat, blocked nose, runny nose, cough,
sneezing and systemic symptoms were defined as head-
ache, muscle ache, and chilliness. Symptoms were
assessed on a 4 point scale: 0 = none (symptom not pre-
sent in previous 24 h), 1 = mild (sensible, but not dis-
turbing or irritating), 2 = moderate (symptoms
sometimes disturbing/irritating), 3 = severe (symptoms
disturbing/irritating most of the time). This scoring sys-
tem was developed by Jackson in 1958 and is widely
used in common cold clinical trials[14]. In order to
recruit subjects with early onset of common cold, on
study entry, subjects had symptom scores of 1 or greater
for sore throat, runny or blocked nose and a total symp-
tom score of 9 or less for the sum of severity scores
comprising headache, muscle ache, chilliness, sore
throat, runny nose, blocked nose, cough, and sneezing.
Study participants agreed to refrain from taking any
other medications intended to prevent, intervene with
or treat coughs/colds/flu-like symptoms, starting with
study entry and continuing through day 7.
Entrants were excluded from the study for the follow-
ing predefined reasons: unwilling to sign the consent
form, a known hypersensitivity or allergy to any compo-
nent of the study medication, a clinically significant car-
diovascular, endocrine, neurological, respiratory, or
gastrointestinal disease or history, or any other current
disease that was considered by the investigator as an
exclusion criteria, e.g. current allergic rhinitis, chronic
obstructive pulmonary disease (COPD). Although not
explicitly mentioned in the study protocol asthma was
such an exclusion criterion and no patients with asthma
were recruited. Furthermore, subjects were also
excluded by the investigator if a severe nasal septum
deviation or other condition was present that could
have caused nasal obstruction, such as nasal polyps or
nasal/sinus surgery in the past, and influenced symptom
scores. Additionally, participants with a history of alco-
hol/substance abuse or on prescription medication/con-
comitant therapy other than for contraception, e.g.
systemic steroids, intranasal medicines, antibiotics, were
also excluded by the investigator. Further reasons for
exclusion were incidence of common cold or flu like
symptoms for more than 48 h, current smoking, rela-
tionship to any study personnel, and administration of
any investigational drug or participation in any other
clinical trial within 4 weeks of entry into our study. All
co-existent diseases or conditions were to be treated in
accordance with prevailing medical practice.
Study design and objective
The current study was designed as a single centre, ran-
domised, double-blind, parallel group, placebo-con-
trolled comparative survey in subjects with early
symptoms of common cold to assess the efficacy of a
0.12% Iota-Carrageenan nasal spray in the early treat-
ment of natural colds. Chosen research design, control
groups and variables assessed are standard for this field
of research, as are the ordinal scales used. A study flow
chart is shown in Figure 1.
Subject randomization was done following verification
of inclusion/exclusion criteria. Neither investigators nor
subjects knew the assigned treatment. Randomization
was performed by providing a each test nasal spray with
a unique code number. Randomized subjects were
assigned a nasal spray at visit 1 (treatment day 1). Sub-
jects completed a daily diary of common cold symptom
scores over 7 days and underwent nasal lavage on day 1
before the first treatment and on days 3 or 4. Nasal dos-
ing of study medication was 3 ×/day for 4 days.
The study was conducted between February and May
2008 at the Common Cold and Nasal Research Centre,
Cardiff School of Biosciences, Cardiff University, UK.
Symptoms and application of treatment was documen-
ted in the patient diary. Coding was performed by CRO
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Bioconsult GmbH (Perchtoldsdorf, Austria) and decod-
ing after trial review and data base lock.
This study was performed in compliance with the ICH
E6 Note for Guidance on Good Clinical Practices
(CPMP/ICH/135/95)5, and the principles of the Declara-
tion of Helsinki, local drug law and standard operating
procedures of the investigator, sponsor and CRO
involved. The study protocol and attached documenta-
tion (consent form, subject information, CRF etc.) were
approved by the responsible South East Wales Local
Research Ethics Committee[15]. The signed study proto-
col was available to the journal editor during the review-
ing process. This trial was registered in the European
clinical trial registry under the Eudract Number 2007-
007577-23.
Study endpoints
The primary efficacy measure was defined prospectively
as the mean total symptom score (TSS) for study days
2- 4 with TSS being the sum of 8 individual symptom
scores as described above. Maximum TSS score was 24
for each recorded time point. For statistical analysis,
TSS of study days 2- 4 were summarized per subject
and individual means calculated.
The secondary efficacy measure was defined prospec-
tively as TSS on separate study days 1/2/3/4/5, as the
mean total systemic symptom score (TSSS) (headache,
muscle ache, chilliness) for study days 2- 4, and TSSS
on separate study days 1/2/3/4/5. Further secondary effi-
cacy variables were local symptom score (LSS) (sore
throat, blocked nose, runny nose, cough, sneezing) mean
of study days 2- 4, and on separate study days 1/2/3/4/5,
and individual symptom scores (ISS) (headache, muscle
ache, chilliness, sore throat, blocked nose, runny nose,
cough, sneezing) on separate study days 1/2/3/4/5.
Exploratory efficacy variables included virus detection/
total viral load, cytokine expression detected in nasal
lavage and subject acceptability of test nasal sprays
using a visual analogue scale (VAS, 1- 10). Furthermore,
data on subjects’ willingness to use the product in the
future via an ordinal scale (strongly agree, agree, dis-
agree, strongly disagree) were collected.
Study medication and dosing
Iota-Carrageenan nasal spray (Verum; unlabelled Colda-
maris prophylactic®) 1,2 g/L, NaCl 5 g/L, water for injec-
tion [WFI] ad 20 ml 20.4 g) and placebo (NaCl 9 g/L,
WFI ad 20 ml 20.4 g) were manufactured by MoNo
chem-pharm Produkte GmbH (Vienna, Austria). Spray
solutions were clear, colourless, odourless and free of
particles. Verum and placebo nasal sprays were identical
in shape, size and colour to allow a double-blind design,
and were randomized at the CRO. Before administra-
tion, the spray was to be shaken and primed until a fine
mist was delivered. One spray application of 140 μl was
delivered to each nostril 3 ×/day for 4 days. On day 1,
the first application was taken at study entry (9 a.m. to
5 p.m.), the next two applications of the spray were
equally spaced through remaining waking hours on day
1. Nasal spray applications on days 2/3/4 were adminis-
tered equally spaced during waking hours. To control
compliance with the study protocol, returned spray bot-
tles were weighted and weights compared to weights on
dispensing, thereby evaluating the weight of medication
taken over the study period. Subject No. 10 (placebo)
missed the first dose on day 1 and 4, the third dose on
day 2, and therefore took only 75% of planned doses.
All other subjects had 100% compliance according to
the diary documentation. In total, 99.3% compliance was
reached in this study. Dependent on the time point of
inclusion in the study, the expected range of difference
in weights was between 2.80 g and 3.36 g. Mean differ-
ence in the verum group was 3.12 g (± 0.84 g), and in
Screened
(n= 35)
Age 19,6y ( 1,2)
randomized
(n= 35)
64,7% female
35,3% male
Verum (n= 17)
Lost to follow up (n=1) 
unknown reason
Excluded due to protocol 
violations (n=2)
Analyzed
(n= 14)
Placebo (n= 18)
Analyzed
(n= 18)
Confirmed virus positive
(n= 6)
Confirmed virus positive
(n= 5)
Figure 1 Flow diagram for study participants including
demographic data.
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placebo group 3.84 g (± 1.85 g) concluding that more
placebo than verum doses were administered. This
result supports the good compliance reported by the
subjects in the diary.
Onset of common cold symptoms (days before visit 1)
is displayed in Additional file 1: Table S1.
Analysis of nasal lavages
Nasal lavage was performed on day 1 (study inclusion)
and on days 3 or 4. Samples were collected by instilla-
tion of 5 ml of 0.9% sterile saline into each nostril,
washes expelled into waxed paper cups, samples pooled
(per subject) before processing at 4°C within 3 h. 8 parts
lavage were mixed with 1 part 5% bovine albumin
(Sigma Aldrich, Vienna, Austria) and 1 part 10× pro-
tease inhibitor cocktail (Roche, Germany), portioned to
5 samples, and stored at -80°C until further analysis.
For the determination of respiratory virus load and
virus identification in nasal lavage, real time PCR analy-
sis was performed for influenza virus type A + B,
respiratory syncytial virus type A + B, parainfluenza
virus types 1/2/3/4, coronavirus types OC43 and 229E,
rhinoviruses (major/minor group viruses), human
metapneumovirus. Assays were performed using
QiAamp Viral RNA Mini and Qiagen QuantiFast Probe
PCR Kits (QIAGEN GmbH, Hilden, Germany), RealAc-
curate Respiratory RT PCR Kit (Pathofinder, Maastricht,
the Netherlands) and Real Time PCR 7900 HT
Sequence Detection (Applied Biosystems, Foster City,
USA) according to the manufacturer’s instructions. This
setup enables detection of 12 RNA viruses that account
for approximately 90% of respiratory tract infections. In
brief, 140 μl samples were thawed on ice, transferred to
560 μl Buffer AVL with carrier RNA, spiked with 10 μl
internal control, and eluated RNA was stored at -20°C
for a maximum of 4 hours until transfer to -80°C. RT-
PCR reaction was performed in a final volume of 20 μl.
The following real-time cycler conditions were used:
30 min reverse transcription at 50°C, 15 min activation
of Taq DNA polymerase and inactivation of reverse
transcriptases at 95°C, 15 s denaturation at 94°C, 60 s
annealing and extension at 55°C, 42 cycles. The ct
values of all positive samples were anti-logged on the
basis of 2. The resulting values of virus positive samples
from the first visit were set 100%. The relative quantity
of virus positive samples at the second visit was calcu-
lated in percent of the value of the first visit.
Lavage samples were assayed in duplicates for mea-
surement of relative cytokine quantity. Cytokine concen-
tration was determined by Milliplex MAP Human
Cytokine/Chemokine Kit 96 Well Plate Assay (Millipore
Corp., St. Charles, USA) according to the manufacturer’s
instruction. 0.9% NaCl was used as matrix complying
with lavage medium and the following cytokines
measured: IL-1 a, IL-1 b, IL-2, IL-3, IL-4, IL-5, IL-6,
IL- 7, IL-8, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-
15, IL-17, EGF, Eotaxin, Fractalkine, G-CSF, GM-CSF,
IFN-g, IP-10, MCP-1, MIP-1 a, MIP-1 b, TNF-a, FGF-
2, GRO (includes GRO alpha, beta and gamma), IFN-
a2, IL-1ra, MCP-3, MDC, sCD40L, VEGF. Fluorescence
was determined in a Luminex 100 reader and data ana-
lysed by Luminex software (Riverside CA, USA) using a
4- parameter logistic curve fitting method. The lower
quantification limit was 3.2 pg/ml, values below were set
to ‘zero’. Duplicates that resulted in only 1 detectable
concentration were omitted from analysis.
Statistical analysis
Comparisons between the groups were done by means
of Mann-Whitney U-tests for continuous variables and
by means of Chi square tests for ordinal or nominal dis-
tributed variables. Tests between treatment groups were
performed by Mann-Whitney U-tests. For tests within
groups, the Wilcoxon matched pairs signed rank test
was used. The trial was designed as an exploratory
study. The magnitude of any effect of the nasal spray on
common cold symptoms was unknown. Based on the
experience of the study centre it was calculated that a
study number of 30 healthy subjects should provide suf-
ficient data to determine if there was any effect on nasal
symptoms and to allow power calculations for any
further studies.
Results
Efficacy of the Iota-Carrageenan nasal spray
35 subjects were screened, enrolled and randomized. One
subject (Iota-Carrageenan) was lost in the follow up after
the initial screening visit and no additional data were
obtained. 34 subjects completed the study drug adminis-
tration and were included in the safety analysis. Demo-
graphic data and a study flow chart are shown in Figure
1. Two subjects were excluded from the analysis of symp-
toms due to protocol violations that were defined as an
exclusion criterion in the study protocol. Subject 11
reported vomiting, nausea and abdominal pain presum-
ably caused by an infection of the gastrointestinal tract
and furthermore used ibuprofen as concomitant medica-
tion. Subject 23 reported migraine that was treated with
ibuprofen and a swollen eye due presumably to an aller-
gic reaction that was treated with an oral anti-histamine
during the observation period. The subject was therefore
excluded from the efficacy analysis of symptoms. In total,
14 Iota-Carrageenan patients and 18 placebo patients
were eligible for analysis of symptoms.
The predefined primary efficacy parameter for the trial
was the difference between Iota-Carrageenan and pla-
cebo in total symptom scores on days 2-4 (TSS 2-4).
Iota-Carrageenan nasal spray was superior to placebo
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(p < 0.046) with respect to the primary endpoint mean
of TSS over days 2-4 (Table 1).
The mean total symptom scores over 7 days are
shown in Figure 2. The efficacy of the Iota-Carrageenan
nasal spray treatment appears to be mainly observable
on the local symptom scores (LSS) sore throat, blocked
nose, runny nose, cough, and sneezing, as there was lit-
tle difference between treatments for the systemic symp-
tom scores (SSS) headache, muscle ache, chilliness
(Figure 2). This is reflected in the results of LSS and
SSS mean of sum on days 2-4 which were lower for
Iota-Carrageenan patients with significance levels of
0.064 and 0.704, respectively (Table 1). While there is
no statistical difference TSS on day 1 (p < 0.231), the
difference is significant on day 3 (p < 0.040) indicating a
faster relief of symptoms in the Iota-Carrageenan group.
Average individual symptoms scores blocked nose,
runny nose, cough, and sneezing were higher for placebo
when compared to verum (Figure 3). The individual
symptoms blocked nose and runny nose show the highest
scores indicating that these symptoms are most bother-
some. For all individual LSS a trend towards superiority
of the Iota-Carrageenan nasal spray can be observed. At
inclusion subjects reported a slightly higher score for the
Iota-Carrageenan group for the symptoms blocked nose,
cough and sore throat. These three symptoms showed an
increase in the placebo group but not in the Iota-Carra-
geenan group at the next reporting time points. This
result suggests that the Iota-Carrageenan nasal spray
treatment has an inhibitory effect on the development of
common cold symptoms shortly after start of therapy.
At the study end point (day 7), placebo patients
reported a mean blocked nose score of 0.78. In contrast,
Iota-Carrageenan patients reported a mean blocked nose
score of 0.42, corresponding to a reduction of approxi-
mately 50% (Figure 3). Further post hoc analysis of this
symptom revealed that 71.4% of Iota-Carrageenan
patients did not report the symptom blocked nose at
the end of the study. In the placebo group only 36.4% of
subjects were free of this symptom.
Antiviral efficacy
Nasal lavages were analyzed by quantitative real time
RT-PCR for the presence of viral genomes. Samples of 6
Iota-Carrageenan and 5 placebo patients were virus
positive. 5 patients tested positive for human rhinovirus,
another 5 patients for coronavirus, and one patient for
parainfluenza 3 virus.
As shown in Figure 4, viral load in the placebo group
increased almost 6- fold (579%), while it dramatically
decreased by 92% in the Iota-Carrageenan group (p <
0.009). This result indicates that the treatment of
patients with Iota Carrageenan nasal spray leads to a
highly statistically significant reduction of viral load in
the nasal cavity, while placebo treatment has no influ-
ence on viral replication at all. The basis for the statisti-
cal analysis and the ct-values are shown in Additional
file 2: Table S2. Nasal lavages of both patients that were
excluded due to protocol violations were tested negative
for respiratory viruses (data not shown).
Analysis of cytokines in nasal lavages
The analysis of cytokines revealed that the median level
of the following cytokines was below the detection limit
of 3,2 pg/ml: EGF, Eotaxin, GM-CSF, IFN-g, IL-12(p70),
IL-13, IL-15, IL-17, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9,
MCP-3, MDC, MIP-1a, MIP-1b, sCD40L, sIL-2Ra,
TGFa, TNF-a, TNF-b, and VEGF. The relatively low
level of these parameters suggested no major biological
relevance at the time point of sampling and conse-
quently no further analysis of above cytokines was car-
ried out.
Cytokine IP-10 (CXCL10) was found to be present in
the highest concentration of all tested cytokines. While
there was a decrease from 1790 pg/ml at the first visit to
an average of 970 pg/ml on day 3/4 in the Iota-Carragee-
nan group there was an increase to 3016 pg/ml in the pla-
cebo group from day 1 to day 3/4 (Table 2). However, due
to a high standard deviation the difference of IP-10 levels
between Iota-Carrageenan and placebo is not significant.
At a much lower level a similar effect was observed for
GRO, G-CSF, IL-8, IL-1a, IL-10, IFN-2a and the differ-
ence was even significant for FGF-2 (p = 0,04) and Frac-
talkine (p = 0,023). In contrast, two molecules that are
known for their function as antagonists of inflammation,
IL-1ra and IL-12(p40), were higher in the Iota-Carragee-
nan group. However, the result allows hypothesizing that
the observed reduction in viral replication resulted in a
Table 1 Study endpoints based on symptoms
End point Carrageenan nasal spray n = 14 Placebo nasal spray n = 18 p-value
Primary endpoint
TSS mean of sum on days 2-4 4.62 ± 2,06 6.28 ± 2.29 0.046
Secondary endpoints
LSS mean of sum on days 2-4 3.79 ± 2,03 5.22 ± 2.30 0.068
SSS mean of sum on days 2-4 0.83 ± 0,75 1.06 ± 1,07 0.704
Shown are symptom scores TSS (total symptom score), LSS (local symptom score), and SSS (systemic symptom score) ± standard deviation.
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lower level of pro-inflammatory cytokines and conse-
quently in a lower symptom score.
Product acceptability
Product acceptability by subjects for Iota-Carrageenan
and placebo nasal spray, respectively, was significantly
higher for Iota-Carrageenan in ITT (p = 0.041), PP (p =
0.009) and also for virus positive patients (p = 0.005)
(Table 3). In PP only 1 subject (7%) using Iota-Carragee-
nan but 6 subjects using placebo (33%) opposed future
consistent medication. It is of note that the placebo for-
mulation was identical to verum except Iota-Carragee-
nan, showing that all components of Iota-Carrageenan
nasal spray are exceptionally well tolerated by the sub-
jects, remarkably with even increasing support by virus-
positive subjects. These results indicate that the
observed benefit of Iota-Carrageenan-treated patients
both on the levels of symptom scores and biomarkers
correlates with a higher product acceptability.
Safety and tolerability
No serious adverse events (SAE) were reported and
there were no withdrawals due to adverse event (AE)
development. AEs were listed by patients including the
reported term by the investigator, the MedDRA Pre-
ferred Term (PT) and the MedDRA System Organ Class
(SOC) [16]. 5 subjects (4 Iota-Carrageenan, 1 placebo)
experienced at least one AE. Iota-Carrageenan patient
11 reported three AEs - vomiting, nausea and abdominal
pain - used ibuprofen as concomitant medication and
was therefore excluded from the efficacy analysis of
symptoms. The AEs were not considered to be asso-
ciated with the study medication. Iota-Carrageenan
patient 23 reported migraine and puffy eye lids, used
ibuprofen and anti-histamine as concomitant medication
and was therefore excluded from the efficacy analysis of
symptoms. One Iota-Carrageenan patient reported a loss
of voice and another Iota-Carrageenan patient reported
a dry mouth. Intermittent epistaxis was reported by a
placebo patient. A total of 8 AEs were reported, 2 were
rated as possibly related to treatment: dry mouth (Iota-
Carrageenan, n = 1) in the ITT and PP groups and
puffy eye lids (Iota-Carrageenan, n = 1) (Additional file
3: Table S3). Since all side effects were resolved, no spe-
cial actions were necessary. The small number of AE
reports supports in particular the good safety-profile of
Iota-Carrageenan as an active agent and Iota-Carragee-
nan nasal spray components in general.
Discussion
The results of this study indicate that the Iota Carragee-
nan nasal spray is a safe and effective treatment when
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Figure 2 Mean symptom scores over 7 days. Mean ± SEM for
Carrageenan nasal spray (black squares) and Placebo (black
triangles) treatment groups. A. Total symptom scores B. Local
Symptom scores C. Systemic symptom scores. The y axis shows the
study day; i indicates the point of inclusion into the study.
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taken within 48 hours of development of common cold
symptoms. Designed as an exploratory trial, the size of
the study was relatively small but reached statistical sig-
nificance (p = 0.046) for the predefined primary end-
point (TSS mean of sum on days 2-4). All patients
reported relatively low levels of systemic symptoms indi-
cating that no severe infection of the respiratory tract
had occurred (Figure 2). The efficacy of the Iota-Carra-
geenan nasal spray treatment appears to be mainly
dependent on the local symptom scores (LSS) sore
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Figure 3 Mean individual symptom scores over 7 days. Mean individual symptom scores ± SEM for Carrageenan nasal spray (black squares)
and Placebo (black triangles) treatment groups. The y axis shows the day of recording. The y axis shows the study day; i indicates the point of
inclusion into the study.
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throat, blocked nose, runny nose, cough, and sneezing
(Table 1, Figure 3).
Interestingly, 63.6% of placebo and only 28.6% of Iota-
Carrageenan patients reported the symptom blocked
nose at the end of the study period. Although not expli-
citly tested, we conclude that the above fact is one of
the main reasons why there was a significantly better
acceptability in patients with the Iota-Carrageenan nasal
spray (Table 3).
Both the Iota-Carrageenan and the placebo group
reached a mean TSS level of around 2 at the end of the
7 day observation period (Figure 2). The study medica-
tion was applied only for the first 4 days. This could be
a reason why a complete relief of symptoms did not
occur in the study period of 7 days. We conclude that
both a longer treatment and observation period should
be considered in future trials for better determination of
the therapeutic effect of the Iota-Carrageenan nasal
spray.
The study population consisted mainly of students
with a mean age of 19.6 (SD 1.2) years, and the compli-
ance was very high. Since this age group reflects only a
small proportion of the general population, this study
might serve as a best case indicator for the design of
bigger trials targeting the population in general. It is
well known from studies with other antiviral substances
that early intervention correlates with efficacy. The vast
majority of patients (>88%) reported symptoms for 1
day or less on the day of inclusion into the study (Addi-
tional file 1: Table S1). We conclude that treatment of
common cold with Iota-Carrageenan nasal sprays is
effective when started early after onset of symptoms.
Iota-Carrageenan nasal spray is formulated as a solu-
tion of Iota-Carrageenan and NaCl in water intended
for direct intranasal application. Tests for effectiveness
of blinding of the study medication were not carried
out. Although the study medication of both groups
appeared completely identical this might be a weakness
of the study. Independent reviews of randomised con-
trolled clinical trials on upper respiratory tract infection
show limited evidence for a benefit of saline nasal irriga-
tion. However, the use of this treatment is widely
accepted and some trials obtained satisfactory results
[17-19]. The nasal cavity is the site of choice for inhibi-
tion of common cold virus infection and replication.
The Iota-Carrageenan effects are complemented by the
known efficacy, safety and patient satisfaction of saline
nasal irrigation in acute or chronic rhino sinusitis via
the NaCl/WFI spray component that served as placebo
in this study.
The symptomatic benefit for Iota-Carrageenan
patients correlated well with the decrease of detectable
virus genome copies in nasal lavages of patients (Figure
4). The statistical analysis of the 11 virus positive
patients revealed a p-value of 0.009 for the difference
between the Iota-Carrageenan nasal spray and the pla-
cebo. Since the number of virus positive-tested subjects
was low, further confirmation of this result is needed. It
cannot be ruled out that some patients were infected
with respiratory viruses that were not tested or were
below the detection limit. However, this result in
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Figure 4 Relative viral load at day 3/4 in % of day 1. Shown is
the relative viral load on day 3/4 in percent of the viral load on
day 1. The mean of the ct values at visit 1 was set 100% for both
Iota-Carrageenan and placebo and the percent of the ct values on
day 3/4 was calculated as described in materials and methods. The
ct numbers of Iota-Carrageenan and placebo samples of day 1 and
day 3/4 were compared by applying a Mann-Whitney U-test
(p = 0.009). The black bar shows Iota-Carrageenan and the grey bar
shows placebo.
Table 2 Analysis of cytokines in nasal lavages
first visit
day 1
second visit
day 3/4
second visit
day 3/4
all Iota-
Carrageenan
Placebo p-value
FGF-2 5.9 (5.9) 2.5 (2.8) 7.5 (5.6) 0.04
Fractalkine 87.0 (74.5) 46.4 (32.4) 79.7 (39.3) 0.023
GRO 252 (233) 156 (112) 339 (417) n.s.
G-CSF 45.5 (89.1) 10.9 (17.9) 78.5 (186) n.s.
IL-8 18.7 (30.6) 14.4 (10.8) 21.0 (22.4) n.s.
IL-1a 35.3 (30.0) 28.8 (14.4) 43.1 (28.9) n.s.
IP-10 1790 (3177) 970 (1769) 3016 (4033) n.s.
IL-10 1.6 (4.22) 0 (0) 5.5 (13.6) 0.049
IL-1ra 164 (129) 174 (320) 131 (85) n.s.
IFN-a2 11.6 (8.0) 8.7 (4.1) 11.5 (5.6) n.s.
IL-12(p40) 10.6 (14.0) 9.1 (9.7) 8.0 (9.8) n.s.
Comparison of cytokine levels on day 1 and day 3/4. Shown are mean levels
in pg/ml ± standard deviation. Lower quantification limit was 3.2 pg/ml,
values below were set to ‘0’. P-values: comparison verum versus placebo by
Mann-Whitney U-test.
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patients further supports earlier in-vitro findings of the
antiviral effect against human rhinoviruses [10] and
against other viruses such a papillomaviruses or dengue
virus [11,13]. The results of this study might encourage
clinical developments for these viruses as well.
Common cold symptoms are caused by the reaction of
the immune system against viruses and virus infected
cells as well as local and newly recruited immune cells.
In nasal lavage samples the presence of immune media-
tors was tested. While the majority of the growth factors
and cytokines were expressed below the detection limit,
11 mediators including IL-8, IP10, and GRO were easily
detectable. It is interesting to note that the expression
of the majority of the molecules (FGF-2, Fractalkine,
GRO, G-CSF, IL-8, IL-1a, IP-10, IL-10, and IFN-a2)
was reduced in the Iota-Carrageenan group upon treat-
ment, while IL-1 receptor antagonist and IL-12p40 were
increased. IL-1 receptor antagonist is regarded as coun-
ter-acting molecule to IL-1. The role of IL-12p40 during
a respiratory infection in humans is not fully under-
stood. A recent study suggested suggest that endogen-
ous IL-12p40 is essential for inhibition of airway
hyperresponsiveness and peribronchial fibrosis, but not
eosinophilic inflammation, in a murine asthma model
with prolonged antigen exposures [20].
The above results suggest that the treatment with
Iota-Carrageenan reduces the viral replication. Conse-
quently fewer cells are infected, the immune reaction
against the viruses is less pronounced and fewer symp-
toms occur. In addition, it is reported that the expres-
sion of pro-inflammatory mediators in the course of a
common cold may worsen pre-existing co-morbidities
such as asthma or COPD [6,21,22]. Therefore, a reduc-
tion of the immune response due to lower viral load
appears as an attractive property of this novel treatment.
The Iota Carrageenan nasal spray used in this study
may reduce the severity of nasal symptoms by an anti-
viral effect rather than any pharmacological effect on
nasal blood vessels and glands. This has some advan-
tages as pharmacological interventions to control symp-
toms such as nasal decongestants and antisecretory
agents are associated with side effects such as nasal
bleeding and crusting [21].
Young children with respiratory symptoms are major
spreaders of rhinovirus in the family setting. Rhinovirus
infections are a common cause of hospitalization of chil-
dren, most often because of wheezing [23,24]. As the
vast bulk of viral transmission occurs among children
and families an intervention affecting the transmission
would be of great socioeconomic value [25]. The lack of
toxicity and pharmacological activity of the Iota Carra-
geenan nasal spray with its high safety profile means
that this treatment may be suitable for use in children
as well as adults.
Conclusions
Iota-Carrageenan nasal spray appears to be a promising
compound for safe and effective treatment of early
symptoms of common cold. Larger clinical trials are
needed to study the therapeutic index in more detail.
Additional material
Additional file 1: Table S1 - Analysis of days of onset of common
cold symptoms. Shown are the numbers of patients for verum, placebo
and total divided into groups with days of onset of common cold
symptoms at the point of inclusion into the study. P-value comes from
Chi square test.
Additional file 2: Table S2 - Viral load of identified viruses, lavage
on study day 1 and 3 or 4. Shown are ct-values of real time PCR: ct
values of 35 - 40 indicative for minimal amounts of target viral nucleic
acid, cts 30 - 35 for moderate amounts, cts < 30 mark strong positive
reactions P-values: comparison verum versus placebo by Mann-Whitney
U-test. Unit: ct value.
Additional file 3: Table S3 - Summary table of adverse events.
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